Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Dose-Response Relationship, Drug"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 178794
Tytuł:
Assessment of the Pharmacokinetics and Safety of Spesolimab, a Humanised Anti-interleukin-36 Receptor Monoclonal Antibody, in Healthy Non-Japanese and Japanese Subjects: Results from Phase I Clinical Studies.
Autorzy:
Joseph D; Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Rd, Ridgefield, CT, 06877, USA.
Thoma C; Boehringer Ingelheim International GmbH, Biberach, Germany.
Haeufel T; Boehringer Ingelheim International GmbH, Ingelheim, Germany.
Li X; Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Rd, Ridgefield, CT, 06877, USA. .
Pokaż więcej
Źródło:
Clinical pharmacokinetics [Clin Pharmacokinet] 2022 Dec; Vol. 61 (12), pp. 1771-1787. Date of Electronic Publication: 2022 Dec 01.
Typ publikacji:
Clinical Trial, Phase I; Journal Article
MeSH Terms:
Dose-Response Relationship, Drug*
Humans ; Double-Blind Method ; Half-Life ; Healthy Volunteers ; Infusions, Intravenous ; Injections, Subcutaneous
Czasopismo naukowe
Szczegóły
Tytuł:
When the usual doses are not enough.
Autorzy:
Macías Reyes MJ; Medicina de Familia, Hospital Universitari d'Igualada, Barcelona, Spain. Electronic address: mariaj_.
Pluma Sanjurjo A; Reumatología, Hospital Universitari de Vall Hebron, Barcelona, Spain.
Marsal Barril S; Reumatología, Hospital Universitari de Vall Hebron, Barcelona, Spain.
Grados Canovas MD; Reumatología, Hospital Universitari d'Igualada, Barcelona, Spain.
Pokaż więcej
Źródło:
Reumatologia clinica [Reumatol Clin (Engl Ed)] 2022 Nov; Vol. 18 (9), pp. 560-561. Date of Electronic Publication: 2021 Nov 10.
Typ publikacji:
Case Reports; Letter
MeSH Terms:
Dose-Response Relationship, Drug*
Arthritis, Rheumatoid*/drug therapy
Certolizumab Pegol*/administration & dosage
Certolizumab Pegol*/therapeutic use
Humans ; Female ; Adult ; Pregnancy ; Pregnancy Complications
Raport
Szczegóły
Tytuł:
Randomized Trial of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2831781 in Healthy Japanese and White Participants.
Autorzy:
Liefaard L; Clinical Pharmacology Modelling and Simulation, GSK, Stevenage, UK.
Hajduk E; Global Clinical Sciences and Delivery, GSK, Brentford, UK.
van den Berg F; Hammersmith Medicines Research, London, UK.
Panoilia E; Clinical Pharmacology Modelling and Simulation, GSK, Stevenage, UK.
Bouma G; Clinical Pharmacology and Experimental Medicine, GSK, Stevenage, UK.
Lisi E; Biostatistics, GSK, Stevenage, UK.
Srinivasan N; Adaptive Immunity Research Unit, GSK, Stevenage, UK.
Cui Y; Global Safety, GSK, Brentford, UK.
Gross AS; Clinical Pharmacology Modelling and Simulation, GSK, Sydney, Australia.
Tarzi R; Clinical Science, GSK, Stevenage, UK.
Marks DJB; Clinical Pharmacology and Experimental Medicine, GSK, Stevenage, UK.
Pokaż więcej
Źródło:
Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2022 Nov; Vol. 11 (11), pp. 1284-1293. Date of Electronic Publication: 2022 Sep 11.
Typ publikacji:
Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Dose-Response Relationship, Drug*
Humans ; Japan ; Double-Blind Method ; Area Under Curve ; Healthy Volunteers
Czasopismo naukowe
Szczegóły
Tytuł:
Nicotine modifies cocaine responding in a concurrent self-administration model.
Autorzy:
Dawes MH; Department of Physiology and Pharmacology, Wake Forest University School of Medicine, Winston-Salem, NC 27101, United States.
Estave PM; Department of Physiology and Pharmacology, Wake Forest University School of Medicine, Winston-Salem, NC 27101, United States; Department of Pediatrics, Wake Forest University School of Medicine, Winston-Salem, NC 27101, United States.
Albertson SE; Department of Physiology and Pharmacology, Wake Forest University School of Medicine, Winston-Salem, NC 27101, United States.
Wallace CW; Department of Physiology and Pharmacology, Wake Forest University School of Medicine, Winston-Salem, NC 27101, United States.
Holleran KM; Department of Physiology and Pharmacology, Wake Forest University School of Medicine, Winston-Salem, NC 27101, United States.
Jones SR; Department of Physiology and Pharmacology, Wake Forest University School of Medicine, Winston-Salem, NC 27101, United States. Electronic address: .
Pokaż więcej
Źródło:
Drug and alcohol dependence [Drug Alcohol Depend] 2023 Oct 01; Vol. 251, pp. 110960. Date of Electronic Publication: 2023 Sep 07.
Typ publikacji:
Journal Article
MeSH Terms:
Cocaine*
Cocaine-Related Disorders*/drug therapy
Substance-Related Disorders*/drug therapy
Rats ; Male ; Animals ; Nicotine ; Rats, Sprague-Dawley ; Self Administration/methods ; Dose-Response Relationship, Drug ; Reinforcement Schedule ; Conditioning, Operant
Czasopismo naukowe
Szczegóły
Tytuł:
Evaluating the clinical effectiveness and safety of insulin glargine 300 U/mL in individuals with type 2 diabetes uncontrolled on basal insulin: A real-world evidence study from Saudi Arabia (EVOLUTION).
Autorzy:
Al Malki F; Al Noor Specialist Hospital, Makkah, Saudi Arabia.
El Damanhoury B; Heraa General Hospital, Makkah, Saudi Arabia.
Othman A; Aseer General Hospital, Asser, Saudi Arabia.
Alghamdi Z; King Fahd General Hospital, Madinah, Saudi Arabia.
AlQahtani M; King Fahd General Hospital, Tabuk, Saudi Arabia.
Madgy A; Sanofi, Jeddah, Saudi Arabia.
Chouikrat Z; Sanofi, Jeddah, Saudi Arabia.
Pokaż więcej
Źródło:
Diabetes, obesity & metabolism [Diabetes Obes Metab] 2023 Oct; Vol. 25 (10), pp. 2869-2877. Date of Electronic Publication: 2023 Jul 24.
Typ publikacji:
Journal Article
MeSH Terms:
Diabetes Mellitus, Type 2*/drug therapy
Diabetes Mellitus, Type 2*/chemically induced
Hypoglycemia*/chemically induced
Hypoglycemia*/epidemiology
Hypoglycemia*/prevention & control
Adult ; Humans ; Insulin Glargine/adverse effects ; Hypoglycemic Agents/adverse effects ; Glycated Hemoglobin ; Retrospective Studies ; Saudi Arabia/epidemiology ; Dose-Response Relationship, Drug ; Treatment Outcome
Czasopismo naukowe
Szczegóły
Tytuł:
Optimisation of warfarin-dosing algorithms for Han Chinese patients with CYP2C9*13 variants.
Autorzy:
Wang D; Cardiovascular Department, Beijing Hospital, National Centre of Gerontology, Beijing, 100730, China.; Fuwai Hospital, Arrhythmia Center, Chinese Academy of Medical Sciences, National Center for Cardiovascular Diseases, 100037, Beijing, China.
Wu H; Cardiovascular Department, Beijing Hospital, National Centre of Gerontology, Beijing, 100730, China.
Zhang Q; Cardiovascular Department, Beijing Hospital, National Centre of Gerontology, Beijing, 100730, China.
Zhou X; Cardiovascular Department, Beijing Hospital, National Centre of Gerontology, Beijing, 100730, China.
An Y; Cardiovascular Department, Beijing Hospital, National Centre of Gerontology, Beijing, 100730, China.
Zhao A; Cardiovascular Department, Beijing Hospital, National Centre of Gerontology, Beijing, 100730, China.
Chong J; Cardiovascular Department, Beijing Hospital, National Centre of Gerontology, Beijing, 100730, China.
Wang S; Laboratory of Clinical Pharmacy, The Sixth Affiliated Hospital of Wenzhou Medical University, The People's Hospital of Lishui, Lishui, 323020, China.
Wang F; Cardiovascular Department, Beijing Hospital, National Centre of Gerontology, Beijing, 100730, China.
Yang J; Cardiovascular Department, Beijing Hospital, National Centre of Gerontology, Beijing, 100730, China.
Dai D; The Key Laboratory of Geriatrics, Beijing Institute of Geriatrics, Beijing Hospital, National Centre of Gerontology, Beijing, 100730, China.
Chen H; Cardiovascular Department, Beijing Hospital, National Centre of Gerontology, Beijing, 100730, China. dr.chenhaomd_.
Pokaż więcej
Źródło:
European journal of clinical pharmacology [Eur J Clin Pharmacol] 2023 Oct; Vol. 79 (10), pp. 1315-1320. Date of Electronic Publication: 2023 Jul 17.
Typ publikacji:
Journal Article
MeSH Terms:
Warfarin*
Anticoagulants*
Humans ; Cytochrome P-450 CYP2C9/genetics ; East Asian People ; Vitamin K Epoxide Reductases/genetics ; Genotype ; Algorithms ; Dose-Response Relationship, Drug
Czasopismo naukowe
Szczegóły
Tytuł:
Pharmacokinetics, pharmacodynamics, safety and tolerability of FTP-198, a novel, selective Autotaxin inhibitor, in healthy subjects: A phase I randomized placebo-controlled trial.
Autorzy:
Yang L; Department of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan University, No. 37 Guoxue Lane, Chengdu, Sichuan, 610044, China; Clinical Trial Center, West China Hospital, Sichuan University, No. 37 Guoxue Lane, Chengdu, Sichuan, 610044, China.
Shu P; Clinical Trial Center, West China Hospital, Sichuan University, No. 37 Guoxue Lane, Chengdu, Sichuan, 610044, China.
Wu N; Haisco Pharmaceutical Group Co., LtPd., Chengdu, China.
Hu M; Haisco Pharmaceutical Group Co., LtPd., Chengdu, China.
Luo Z; Clinical Trial Center, West China Hospital, Sichuan University, No. 37 Guoxue Lane, Chengdu, Sichuan, 610044, China. Electronic address: .
Pokaż więcej
Źródło:
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences [Eur J Pharm Sci] 2023 Oct 01; Vol. 189, pp. 106552. Date of Electronic Publication: 2023 Jul 31.
Typ publikacji:
Randomized Controlled Trial; Clinical Trial, Phase I; Journal Article
MeSH Terms:
Idiopathic Pulmonary Fibrosis*/drug therapy
Humans ; Healthy Volunteers ; Area Under Curve ; Administration, Oral ; Half-Life ; Double-Blind Method ; Dose-Response Relationship, Drug
Czasopismo naukowe
Szczegóły
Tytuł:
Novel 1,2,4-triazoles derived from Ibuprofen: synthesis and in vitro evaluation of their mPGES-1 inhibitory and antiproliferative activity.
Autorzy:
Bülbül B; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Düzce University, Konuralp, Düzce, Turkey.; Department of Pharmaceutical Chemistry, Institute of Health Sciences, Marmara University, Dragos, Kartal, 34865, Istanbul, Turkey.
Ding K; Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, 789 South Limestone Street, Lexington, KY, 40536, USA.; Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, 789 South Limestone Street, Lexington, KY, 40536, USA.
Zhan CG; Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, 789 South Limestone Street, Lexington, KY, 40536, USA.; Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, 789 South Limestone Street, Lexington, KY, 40536, USA.
Çiftçi G; Department of Bioinformatics and Genetics, Faculty of Engineering and Natural Sciences, Kadir Has University, Istanbul, Turkey.
Yelekçi K; Department of Bioinformatics and Genetics, Faculty of Engineering and Natural Sciences, Kadir Has University, Istanbul, Turkey.
Gürboğa M; Department of Biochemistry, Faculty of Pharmacy, Marmara University, Haydarpaşa, 34668, Istanbul, Turkey.
Özakpınar ÖB; Department of Biochemistry, Faculty of Pharmacy, Marmara University, Haydarpaşa, 34668, Istanbul, Turkey.
Aydemir E; Department of Genetics and Bioengineering, Faculty of Engineering, Yeditepe University, Kayışdağı, Istanbul, Turkey.; Department of Biomedical Engineering, Faculty of Engineering and Natural Sciences, Biruni University, Zeytinburnu, 34010, Turkey.
Baybağ D; Department of Genetics and Bioengineering, Faculty of Engineering, Yeditepe University, Kayışdağı, Istanbul, Turkey.
Şahin F; Department of Genetics and Bioengineering, Faculty of Engineering, Yeditepe University, Kayışdağı, Istanbul, Turkey.
Kulabaş N; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Marmara University, Başıbüyük, 34854, Istanbul, Turkey.
Helvacıoğlu S; Department of Toxicology, Faculty of Pharmacy, Yeditepe University, Ataşehir, 34750, Istanbul, Turkey.
Charehsaz M; Department of Toxicology, Faculty of Pharmacy, Yeditepe University, Ataşehir, 34750, Istanbul, Turkey.
Tatar E; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Marmara University, Başıbüyük, 34854, Istanbul, Turkey.
Özbey S; Department of Physics Engineering, Faculty of Engineering, Hacettepe University, Beytepe, 06800, Ankara, Turkey.
Küçükgüzel İ; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Marmara University, Başıbüyük, 34854, Istanbul, Turkey. .
Pokaż więcej
Źródło:
Molecular diversity [Mol Divers] 2023 Oct; Vol. 27 (5), pp. 2185-2215. Date of Electronic Publication: 2022 Nov 04.
Typ publikacji:
Journal Article
MeSH Terms:
Ibuprofen*/pharmacology
Antineoplastic Agents*/pharmacology
Animals ; Mice ; Female ; Humans ; Structure-Activity Relationship ; Triazoles/pharmacology ; Fibroblasts ; HeLa Cells ; Anti-Inflammatory Agents/pharmacology ; Cell Proliferation ; Drug Screening Assays, Antitumor ; Molecular Structure ; Cell Line, Tumor ; Dose-Response Relationship, Drug
Czasopismo naukowe
Szczegóły
Tytuł:
Population pharmacokinetics of voriconazole and the role of CYP2C19 genotype on treatment optimization in pediatric patients.
Autorzy:
Hu L; Department of Pharmacy, The First Hospital of Changsha, Changsha, Hunan, China.
Huang S; Department of Pharmacy, The First Hospital of Changsha, Changsha, Hunan, China.
Huang Q; Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Huang J; Department of Pharmacy, The First Hospital of Changsha, Changsha, Hunan, China.
Feng Z; Clinical Trial Institution Office, Liuzhou Hospital of Guangzhou Women and Children's Medical Center, Liuzhou, Guangxi, China.; Center of Clinical Pharmacology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
He G; Department of Pharmacy, The First Hospital of Changsha, Changsha, Hunan, China.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2023 Sep 11; Vol. 18 (9), pp. e0288794. Date of Electronic Publication: 2023 Sep 11 (Print Publication: 2023).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antifungal Agents*/blood
Antifungal Agents*/pharmacokinetics
Asian People*/genetics
Drug Monitoring*
Voriconazole*/blood
Voriconazole*/pharmacokinetics
Child ; Humans ; Administration, Intravenous ; Cytochrome P-450 CYP2C19/genetics ; Dose-Response Relationship, Drug ; Genotype ; Administration, Oral
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
OCE-205, A Novel, Selective Vasopressin Receptor Mixed Agonist-Antagonist: Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics from a Phase 1 Study in Healthy Volunteers.
Autorzy:
Bagger Y; Ferring Pharmaceuticals A/S, Copenhagen, Denmark.
Ravis WR; Ocelot Bio, Inc., 601 Marshall Street, Redwood City, CA, 94063, USA.
Harris G; Ocelot Bio, Inc., 601 Marshall Street, Redwood City, CA, 94063, USA.
Bukofzer S; Ocelot Bio, Inc., 601 Marshall Street, Redwood City, CA, 94063, USA. .
Pokaż więcej
Źródło:
Clinical drug investigation [Clin Drug Investig] 2023 Sep; Vol. 43 (9), pp. 709-717. Date of Electronic Publication: 2023 Aug 22.
Typ publikacji:
Randomized Controlled Trial; Clinical Trial, Phase I; Journal Article
MeSH Terms:
End Stage Liver Disease*
Hypertension*
Adult ; Humans ; Receptors, Vasopressin ; Healthy Volunteers ; Blood Pressure ; Area Under Curve ; Double-Blind Method ; Dose-Response Relationship, Drug
Czasopismo naukowe
Szczegóły
Tytuł:
Analysis of Quinolinequinone Analogs with Promising Cytotoxic Activity against Breast Cancer.
Autorzy:
Yilmaz Goler AM; Department of Biochemistry, School of Medicine/Genetic and Metabolic Diseases Research and Investigation Center, Marmara University, 34854, İstanbul, Türkiye.
Tarbin Jannuzzi A; Department of Pharmaceutical Toxicology, Faculty of Pharmacy, İstanbul University, 34116, İstanbul, Türkiye.
Biswas A; Department of Pharmaceutical Sciences & Technology, Birla Institute of Technology, Mesra, 835215, Ranchi, Jharkhand, India.
Mondal S; Bioanalysis, Eurofins Advinus BioPharma Services India Pvt Ltd., 560058, Bengaluru, India.
Basavanakatti VN; Adgyl Lifesciences Private Limited, 560058, Bengaluru, India.
Jayaprakash Venkatesan R; Department of Industrial and Systems Engineering, Faculty of Interdisciplinary Sciences & Engineering, Indian Institute of Technology, 721302, Kharagpur, India.
Yıldırım H; Department of Chemistry, Engineering Faculty, Istanbul University-Cerrahpasa, Avcilar, 34320, İstanbul, Türkiye.
Yıldız M; Department of Chemistry, Gebze Technical University, Gebze, 41400, Kocaeli, Türkiye.
Çelik Onar H; Department of Chemistry, Engineering Faculty, Istanbul University-Cerrahpasa, Avcilar, 34320, İstanbul, Türkiye.
Bayrak N; Department of Chemistry, Faculty of Science, Istanbul University, Fatih, 34126, İstanbul, Türkiye.
Jayaprakash V; Department of Pharmaceutical Sciences & Technology, Birla Institute of Technology, Mesra, 835215, Ranchi, Jharkhand, India.
TuYuN AF; Department of Chemistry, Faculty of Science, Istanbul University, Fatih, 34126, İstanbul, Türkiye.
Pokaż więcej
Źródło:
Chemistry & biodiversity [Chem Biodivers] 2023 Sep; Vol. 20 (9), pp. e202300848. Date of Electronic Publication: 2023 Aug 23.
Typ publikacji:
Journal Article
MeSH Terms:
Breast Neoplasms*
Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/chemistry
Colonic Neoplasms*
Prostatic Neoplasms*
Kidney Neoplasms*
Melanoma*
Ovarian Neoplasms*
Leukemia*
Humans ; Male ; Female ; Molecular Structure ; Structure-Activity Relationship ; Cell Line, Tumor ; Cell Proliferation ; Drug Screening Assays, Antitumor ; Molecular Docking Simulation ; Dose-Response Relationship, Drug
Czasopismo naukowe
Szczegóły
Tytuł:
Effects of ambient temperature on locomotor activity and place conditioning elicited by abused psychostimulants in mice: Role of 3,4-methylenedioxy moiety.
Autorzy:
Gannon BM; Department of Pharmacology and Toxicology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Fitzgerald LR; Department of Pharmacology and Toxicology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Godwin CO; Department of Pharmacology and Toxicology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Hughes-Meredith HD; Department of Pharmacology and Toxicology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Rice KC; Drug Design and Synthesis Section, Chemical Biology Research Branch, National Institute on Drug Abuse, and the National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA.
Fantegrossi WE; Department of Pharmacology and Toxicology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA. Electronic address: .
Pokaż więcej
Źródło:
Drug and alcohol dependence [Drug Alcohol Depend] 2023 Sep 01; Vol. 250, pp. 110917. Date of Electronic Publication: 2023 Aug 08.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms:
Central Nervous System Stimulants*/adverse effects
Conditioning, Operant*/drug effects
Conditioning, Operant*/physiology
Locomotion*/drug effects
Locomotion*/physiology
N-Methyl-3,4-methylenedioxyamphetamine*/adverse effects
Synthetic Cathinone*/adverse effects
Temperature*
Animals ; Male ; Mice ; Dose-Response Relationship, Drug ; Hallucinogens/adverse effects ; Substance-Related Disorders/physiopathology ; Disease Models, Animal
Czasopismo naukowe
Szczegóły
Tytuł:
Phase Ia dose-escalation trial with the BET protein inhibitor BI 894999 in patients with advanced or metastatic solid tumours.
Autorzy:
Schöffski P; Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium. Electronic address: .
Machiels JP; Department of Medical Oncology, Institut Roi Albert II, Cliniques Universitaires Saint-Luc, and Institute for Experimental and Clinical Research (IREC, pôle MIRO), Université Catholique de Louvain (UCLouvain), Brussels, Belgium.
Rottey S; Department of Medical Oncology, Ghent University Hospital, Ghent, Belgium.
Sadrolhefazi B; Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT, USA.
Musa H; Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.
Marzin K; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany.
Awada A; Oncology Medicine Department, Jules Bordet Institute, Brussels, Belgium.
Pokaż więcej
Źródło:
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2023 Sep; Vol. 191, pp. 112987. Date of Electronic Publication: 2023 Jul 11.
Typ publikacji:
Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Neoplasms*/drug therapy
Neoplasms*/pathology
Humans ; Benzene Derivatives ; Maximum Tolerated Dose ; Dose-Response Relationship, Drug
Czasopismo naukowe
Szczegóły
Tytuł:
Population Target-Mediated Pharmacokinetic/Pharmacodynamic Modeling to Evaluate SPI-62 Exposure and Hepatic 11β-Hydroxysteroid Dehydrogenase Type 1 (HSD-1) Inhibition in Healthy Adults.
Autorzy:
Wu N; Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, 115 S Grand Ave, Iowa City, IA, 52242, USA.
Katz DA; Sparrow Pharmaceuticals, Inc., Portland, OR, USA.
An G; Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, 115 S Grand Ave, Iowa City, IA, 52242, USA. .
Pokaż więcej
Źródło:
Clinical pharmacokinetics [Clin Pharmacokinet] 2023 Sep; Vol. 62 (9), pp. 1275-1288. Date of Electronic Publication: 2023 Jul 15.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
11-beta-Hydroxysteroid Dehydrogenase Type 1*
Software*
Humans ; Adult ; Computer Simulation ; Dose-Response Relationship, Drug ; Drug Delivery Systems/methods ; Models, Biological
Czasopismo naukowe
Szczegóły
Tytuł:
First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of MHV370, a Dual Inhibitor of Toll-Like Receptors 7 and 8, in Healthy Adults.
Autorzy:
Shisha T; Novartis Pharma AG, Novartis Institutes for BioMedical Research, 4002, Basel, Switzerland. .
Posch MG; Charité Research Organisation GmbH, Berlin, Germany.
Lehmann J; Charité Research Organisation GmbH, Berlin, Germany.
Feifel R; Novartis Pharma AG, Novartis Institutes for BioMedical Research, 4002, Basel, Switzerland.
Junt T; Novartis Pharma AG, Novartis Institutes for BioMedical Research, 4002, Basel, Switzerland.
Hawtin S; Novartis Pharma AG, Novartis Institutes for BioMedical Research, 4002, Basel, Switzerland.
Schuemann J; Novartis Pharma AG, Novartis Institutes for BioMedical Research, 4002, Basel, Switzerland.
Avrameas A; Novartis Pharma AG, Novartis Institutes for BioMedical Research, 4002, Basel, Switzerland.
Danekula R; Novartis Pharma AG, Novartis Institutes for BioMedical Research, 4002, Basel, Switzerland.
Misiolek P; Novartis Pharma AG, Novartis Institutes for BioMedical Research, 4002, Basel, Switzerland.
Siegel R; Novartis Pharma AG, Novartis Institutes for BioMedical Research, 4002, Basel, Switzerland.
Gergely P; Novartis Pharma AG, Novartis Institutes for BioMedical Research, 4002, Basel, Switzerland.
Pokaż więcej
Źródło:
European journal of drug metabolism and pharmacokinetics [Eur J Drug Metab Pharmacokinet] 2023 Sep; Vol. 48 (5), pp. 553-566. Date of Electronic Publication: 2023 Aug 02.
Typ publikacji:
Randomized Controlled Trial; Clinical Trial, Phase I; Journal Article
MeSH Terms:
Toll-Like Receptor 7*
Toll-Like Receptor 8*
Humans ; Adult ; Animals ; Mice ; Area Under Curve ; Fasting ; Administration, Oral ; Double-Blind Method ; Dose-Response Relationship, Drug ; Healthy Volunteers
Czasopismo naukowe
Szczegóły
Tytuł:
Sex differences in acute delta-9-tetrahydrocannabinol (Δ -THC) response and tolerance as a function of mouse strain.
Autorzy:
Lulek CF; Department of Biomedical Sciences, Marshall University, Huntington, WV, 25755, USA.
Maulik M; Department of Biomedical Sciences, Marshall University, Huntington, WV, 25755, USA.
Mitra S; Department of Biomedical Sciences, Marshall University, Huntington, WV, 25755, USA.
Guindon J; Department of Pharmacology and Neuroscience, Texas Tech University Health Sciences Center, Lubbock, TX, 79430, USA.
Morgan DJ; Department of Biomedical Sciences, Marshall University, Huntington, WV, 25755, USA.
Henderson-Redmond AN; Department of Biomedical Sciences, Marshall University, Huntington, WV, 25755, USA. .
Pokaż więcej
Źródło:
Psychopharmacology [Psychopharmacology (Berl)] 2023 Sep; Vol. 240 (9), pp. 1987-2003. Date of Electronic Publication: 2023 Jul 29.
Typ publikacji:
Journal Article
MeSH Terms:
Dronabinol*/pharmacology
Cannabinoids*/pharmacology
Mice ; Rats ; Female ; Male ; Animals ; Sex Characteristics ; Mice, Inbred CBA ; Mice, Inbred DBA ; Mice, Inbred C57BL ; Analgesics/pharmacology ; Dose-Response Relationship, Drug
Czasopismo naukowe
Szczegóły
Tytuł:
Phase I, Randomized, Placebo-Controlled, Dose-Escalation Study of GB223, a Fully-Humanized Monoclonal Antibody to RANKL, in Healthy Chinese Adults.
Autorzy:
Li C; Department of Pharmacy, Key Laboratory of Biological Targeting Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.; Phase I Clinical Research Center, Key Laboratory of Biological Targeting Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Liu H; Phase I Clinical Research Center, Key Laboratory of Biological Targeting Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Liao Y; Phase I Clinical Research Center, Key Laboratory of Biological Targeting Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Zhu Y; Department of Pharmacy, Key Laboratory of Biological Targeting Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Tian J; Department of Pharmacy, Key Laboratory of Biological Targeting Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Wang X; Phase I Clinical Research Center, Key Laboratory of Biological Targeting Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Hu Z; Department of Pharmacy, Key Laboratory of Biological Targeting Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Zhan Y; Phase I Clinical Research Center, Key Laboratory of Biological Targeting Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Li X; Phase I Clinical Research Center, Key Laboratory of Biological Targeting Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Liang X; Department of Pharmacy, Key Laboratory of Biological Targeting Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
He J; Department of Pharmacy, Key Laboratory of Biological Targeting Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Li Y; Department of Pharmacy, Key Laboratory of Biological Targeting Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Shang D; Department of Pharmacy, The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, China.
Zheng Q; Center for Drug Clinical Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Wang T; Department of Pharmacy, Key Laboratory of Biological Targeting Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. .
Song H; Department of Pharmacology and Toxicology, Beijing Institute of Radiation Medicine, Beijing, China. .
Fang Y; Clinical Trial Institution Research Ward, Peking University People's Hospital, Beijing, China. .
Pokaż więcej
Źródło:
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy [BioDrugs] 2023 Sep; Vol. 37 (5), pp. 721-735. Date of Electronic Publication: 2023 Jun 06.
Typ publikacji:
Randomized Controlled Trial; Clinical Trial, Phase I; Journal Article
MeSH Terms:
Antibodies, Monoclonal, Humanized*/administration & dosage
Antibodies, Monoclonal, Humanized*/pharmacokinetics
RANK Ligand*
Adult ; Female ; Humans ; Male ; Dose-Response Relationship, Drug ; Double-Blind Method ; East Asian People ; Healthy Volunteers
Czasopismo naukowe
Szczegóły
Tytuł:
A phase 1 study in healthy participants to characterize the safety and pharmacology of inclacumab, a fully human anti-P-selectin antibody, in development for treatment of sickle cell disease.
Autorzy:
Mayer CL; Semivida Research, Dallas, TX, USA. .
Koeck K; Certara USA, Inc., Princeton, NJ, USA.
Hottmann M; Pfizer Inc, New York, NY, USA.
Redfern A; Linear Clinical Research, Nedlands, WA, Australia.
Davis M; Pfizer Inc, New York, NY, USA.
Barth A; Pfizer Inc, New York, NY, USA.
Geng X; Pfizer Inc, New York, NY, USA.
Hoppe C; Pfizer Inc, New York, NY, USA.
Yue P; Pfizer Inc, New York, NY, USA.
Pokaż więcej
Źródło:
European journal of clinical pharmacology [Eur J Clin Pharmacol] 2023 Sep; Vol. 79 (9), pp. 1219-1228. Date of Electronic Publication: 2023 Jul 12.
Typ publikacji:
Clinical Trial, Phase I; Journal Article
MeSH Terms:
Antibodies, Monoclonal*/adverse effects
Anemia, Sickle Cell*/drug therapy
Anemia, Sickle Cell*/chemically induced
Humans ; Healthy Volunteers ; Selectins ; Polyesters ; Double-Blind Method ; Dose-Response Relationship, Drug
Czasopismo naukowe
Szczegóły
Tytuł:
A phase I randomized, double-blinded, placebo-controlled study assessing the safety and pharmacokinetics of RIPK1 inhibitor GFH312 in healthy subjects.
Autorzy:
Lickliter J; Nucleus Network, Melbourne, Victoria, Australia.
Wang S; Genfleet Therapeutics, Shanghai, China.
Zhang W; Genfleet Therapeutics, Shanghai, China.
Zhu H; Genfleet Therapeutics, Shanghai, China.
Wang J; Genfleet Therapeutics, Shanghai, China.
Zhao C; Genfleet Therapeutics, Shanghai, China.
Shen H; Genfleet Therapeutics, Shanghai, China.
Wang Y; Genfleet Therapeutics, Shanghai, China.
Pokaż więcej
Źródło:
Clinical and translational science [Clin Transl Sci] 2023 Sep; Vol. 16 (9), pp. 1691-1703. Date of Electronic Publication: 2023 Jul 04.
Typ publikacji:
Randomized Controlled Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Leukocytes, Mononuclear*
Receptor-Interacting Protein Serine-Threonine Kinases*
Adult ; Humans ; Healthy Volunteers ; Area Under Curve ; Double-Blind Method ; Dose-Response Relationship, Drug
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
First-in-human phase 1 trial evaluating safety, pharmacokinetics, and pharmacodynamics of NLRP3 inflammasome inhibitor, GDC-2394, in healthy volunteers.
Autorzy:
Tang F; Genentech, Inc., South San Francisco, California, USA.
Kunder R; Genentech, Inc., South San Francisco, California, USA.
Chu T; Genentech, Inc., South San Francisco, California, USA.
Hains A; Genentech, Inc., South San Francisco, California, USA.
Nguyen A; Genentech, Inc., South San Francisco, California, USA.
McBride JM; Genentech, Inc., South San Francisco, California, USA.
Zhong Y; Genentech, Inc., South San Francisco, California, USA.
Santagostino S; Genentech, Inc., South San Francisco, California, USA.
Wilson M; Genentech, Inc., South San Francisco, California, USA.
Trenchak A; Genentech, Inc., South San Francisco, California, USA.
Chen L; Genentech, Inc., South San Francisco, California, USA.
Ly J; Genentech, Inc., South San Francisco, California, USA.
Moein A; Genentech, Inc., South San Francisco, California, USA.
Lewin-Koh N; Genentech, Inc., South San Francisco, California, USA.
Raghavan V; Genentech, Inc., South San Francisco, California, USA.
Osaghae U; Genentech, Inc., South San Francisco, California, USA.
Wynne C; Christchurch Clinical Studies Trust Ltd., New Zealand Clinical Research, Christchurch, New Zealand.
Owen R; Genentech, Inc., South San Francisco, California, USA.
Place D; Genentech, Inc., South San Francisco, California, USA.
Pokaż więcej
Źródło:
Clinical and translational science [Clin Transl Sci] 2023 Sep; Vol. 16 (9), pp. 1653-1666. Date of Electronic Publication: 2023 Jul 23.
Typ publikacji:
Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Inflammasomes*
NLR Family, Pyrin Domain-Containing 3 Protein*
Humans ; Healthy Volunteers ; Cytochrome P-450 CYP3A ; Dose-Response Relationship, Drug ; Double-Blind Method ; Administration, Oral
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 1-20 z 178794

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies